You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The assay, called the single telomere absolute-length rapid (STAR) assay, uses Fluidigm microfluidic chips and was found to be accurate and sensitive.
The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.
In PNAS this week: characterization of an alternatively spliced autism-linked gene, horizontal gene transfer in soil bacteria, and more.
The researchers reported that most of these changes, though not all, reverted to normal upon the astronaut's return to Earth.
The assay will use Genomic Vision technology and be used to study the role of telomere length in complex diseases.
The companies will co-fund a new study of the 3DS technology, and MDxHealth will have the option to exclusively license the telomere-based test.
Researchers report that the telomeres of a long-lived bat don't shorten with age.
A null mutation in the SERPINE1 gene was associated with longer telomeres and increased longevity among carriers, a new study found.
Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.
The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.